Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 11/20 | 0.78 |
| ▸ | RAF1 | P04049 | 6/20 | 0.78 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 6/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.54 |
| ▸ | STK4 | Q13043 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29556194 | 1.00 | MAP2K1 (0.78) | MAP2K1RAF1LRRK2KDM1AEGFR | |
| SCHEMBL6691519 | 0.90 | MAP2K1 (0.68) | MAP2K1RAF1LRRK2EGFRERBB2 | |
| Quinoline SCHEMBL28280298 | 0.89 | MAP2K1 (0.65) | MAP2K1RAF1LRRK2KDM1AEGFR | |
| SCHEMBL27707570 | 0.88 | MAP2K1 (1.00) | MAP2K1RAF1LRRK2ERBB2 | |
| SCHEMBL6830483 | 0.87 | MAP2K1 (0.62) | MAP2K1RAF1LRRK2EGFRERBB2 | |
| SCHEMBL868127 | 0.85 | MAP2K1 (0.60) | MAP2K1RAF1LRRK2EGFRERBB2 | |
| SCHEMBL6380413 | 0.85 | MAP2K1 (0.66) | MAP2K1RAF1LRRK2KDM1AEGFR | |
| SCHEMBL27728068 | 0.85 | EGFR (0.68) | MAP2K1RAF1LRRK2EGFRERBB2 | |
| SCHEMBL27459387 | 0.85 | EGFR (0.72) | MAP2K1RAF1EGFRERBB2 | |
| SCHEMBL31297107 | 0.85 | MAP2K1 (0.80) | MAP2K1RAF1LRRK2EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115990181-A | Antitumor combinations of 4-anilino-3-cyanoquinoline and capecitabine | 惠氏有限责任公司 | 2023-04-21 | — | — | CN | claimed |
| CN-113209121-A | Antitumor combination of 4-anilino-3-cyanoquinoline and capecitabine | 惠氏有限责任公司 | 2021-08-06 | — | — | CN | claimed |
| CN-109464445-A | The antineoplastic combinations of 4- anilino- -3- cyano quinolines and capecitabine | 惠氏有限责任公司 | 2019-03-15 | — | — | CN | claimed |
| JP-2011529968-A | — | — | 2011-12-15 | — | — | JP | claimed |
| CN-102202667-A | Antitumor combination of 4-anilino-3-cyanoquinoline and capecitabine | WYETH CORP | 2011-09-28 | — | — | CN | claimed |
| EP-2326329-A1 | ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | Wyeth LLC (US) | 2011-06-01 | — | — | EP | claimed |
| US-20100113474-A1 | Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine | WYETH (US) | 2010-05-06 | — | — | US | claimed |
| WO-2010017163-A1 | ANTINEOPLASTIC COMBINATIONS OF 4-ANILINO-3-CYANOQUINOLINES AND CAPECITABINE | WYETH (US) | 2010-02-11 | — | — | WO | claimed |
| EP-1567160-A4 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | SCRIPPS RESEARCH INST (US) | 2009-06-10 | — | — | EP | claimed |
| CN-101420979-A | Method of treatment of myocardial infarction | SCRIPPS RESEARCH INST (US) | 2009-04-29 | — | — | CN | claimed |
| US-20080200481-A1 | Method of treatment of myocardial infarction | THE SCRIPPS RESEARCH INSTITUTE | 2008-08-21 | — | — | US | claimed |
| EP-1744735-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | The Scripps Research Institute (US) | 2007-01-24 | — | — | EP | claimed |
| US-20060258686-A1 | Method of treatment of myocardial infarction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-11-16 | — | — | US | claimed |
| US-20060167021-A1 | Inhibition of src for treatment of reperfusion injury related to revascularization | CARITAS ST. ELIZABETH'S MEDICAL CENTER OF BOSTON, INC. (US) | 2006-07-27 | — | — | US | claimed |
| CN-1738624-A | Method of treatment of myocardial infarction | SCRIPPS RESEARCH INST (US) | 2006-02-22 | — | — | CN | claimed |
| WO-2005089366-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1567160-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | The Scripps Research Institute (US) | 2005-08-31 | — | — | EP | claimed |
| US-20040214836-A1 | Method of treatment of myocardial infarction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-10-28 | — | — | US | claimed |
| WO-2004045563-A2 | METHOD OF TREATMENT OF MYOCARDIAL INFARCTION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-06-03 | — | — | WO | claimed |
| WO-2004032709-A2 | INHIBITION OF SRC FOR TREATMENT OF REPERFUSION INJURY RELATED TO REVASCULARIZATION | CARITAS ST.ELISABETH'S MEDICAL CENTER OF BOSTON, INC. (US) | 2004-04-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214836-A1 | Method of treatment of myocardial infarction | SRC, LCK, DSTYK | MAP2K1 203/4885RAF1 309/4885LRRK2 2420/4885 |
| US-20100113474-A1 | Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine | HK2, HK1, HEXB | MAP2K1 530/4885RAF1 1338/4885LRRK2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.